Abstract
In early 2021, the SARS-CoV-2 lineage B.1.1.7 became dominant across large parts of the world. In Denmark, comprehensive and real-time test, contact-tracing, and sequencing efforts were applied to sustain epidemic control. Here, we use these data to investigate the transmissibility, introduction, and onward transmission of B.1.1.7 in Denmark. In a period with stable restrictions, we estimated an increased B.1.1.7 transmissibility of 58% (95% CI: [56%,60%]) relative to other lineages. Epidemiological and phylogenetic analyses revealed that 37% of B.1.1.7 cases were related to the initial introduction in November 2020. Continuous introductions contributed substantially to case numbers, highlighting the benefit of balanced travel restrictions and self-isolation procedures coupled with comprehensive surveillance efforts, to sustain epidemic control in the face of emerging variants.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
VILLUM FONDEN grant (15510) (MA) Poul Due Jensen Foundation (Corona Danica) (MA) Styrelsen for Forskning og Uddannelse (0238-00002B) (MA)
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was conducted on administrative register data. According to Danish law, ethics approval is not needed for such research. All data management and analyses were carried out on the Danish Health Data Authority's servers with restricted access. The publication only contains aggregated results and no personal data. The publication is, therefore, not covered by the European General Data Protection Regulation.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Data Availability
This study was conducted on administrative register data. According to Danish law, informed consent is not needed for such research as the publication only contains aggregated results and no personal data is shown. The epidemiological data used in this work is person-sensitive and we are prohibited to make it publicly available according to Danish legislation. SARS-CoV-2 consensus genome sequences associated with this work have been uploaded to the GISAID database in accordance with Danish law (no. 285 vers. 2021-02-27). As consequence, dates are binned by week and maximum spatial resolution is at regional level. Accession numbers are available at https://github.com/TYMichaelsen/B117-DK-introduction. All code used to run the phylogenetic analysis, Poisson regression models, and generate the visualizations used in this work is available at https://github.com/TYMichaelsen/B117-DK-introduction.
